

SECURITIES AND EXCHANGE COMMISSION

FORM CT ORDER

Confidential treatment order

Filing Date: **2013-01-14**  
SEC Accession No. [999999997-13-000227](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**DYAX CORP**

CIK:[907562](#) | IRS No.: **043053198** | State of Incorp.:**DE** | Fiscal Year End: **1231**  
Type: **CT ORDER** | Act: **34** | File No.: **000-24537** | Film No.: **13527810**  
SIC: **8731** Commercial physical & biological research

Mailing Address  
*55 NETWORK DRIVE  
BURLINGTON MA  
01803-2756*

Business Address  
*55 NETWORK DRIVE  
BURLINGTON MA  
01803-2756  
617-250-5769*

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
January 14, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Dyax Corp.**

**File No. 000-24537 - CF#29204**

---

Dyax Corp. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 12, 2010.

Based on representations by Dyax Corp. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.19                      through December 31, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Pamela Howell  
Special Counsel